Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab

Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab

<b><i>Background:</i></b> Bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody commonly used for the treatment of various cancers, is often associated with adverse cardiovascular effects such as hypertension, cardiac and cerebral ischemia, thrombosis,...

Full description

Bibliographic Details
Main Authors: Doan T. M. Ngo, Trent Williams, Sophie Horder, Leonard Kritharides, Janette Vardy, Hiren Mandaliya, Ina I. C. Nordman, James Lynam, Tony Bonaventura, Aaron L. Sverdlov
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Journal of Clinical Medicine
Subjects:
bevacizumab
VEGF inhibitors
cardiovascular risk
complications
outcomes
Online Access:https://www.mdpi.com/2077-0383/9/8/2664

Internet

https://www.mdpi.com/2077-0383/9/8/2664

Similar Items